An overview of the feasibility of nanomedicine in pancreatic cancer theranostics

Kyriakos Kokkinogoulis , Aristomenis Kollas , David Simeonidis , Pavlos Papakostas , Kalliopi Platoni , Efstathios P. Efstathopoulos , Mersini Makropoulou

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002326

PDF (3099KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002326 DOI: 10.37349/etat.2025.1002326
Review
research-article
An overview of the feasibility of nanomedicine in pancreatic cancer theranostics
Author information +
History +
PDF (3099KB)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the top causes of cancer-induced mortality, frequently diagnosed too late to be treated effectively, due to the poor prognosis and the limited successful therapeutic options. Apart from the conventional treatments, new multimodal therapies have emerged utilizing different scientific fields for the improvement of the survival and quality of patients’ lives. The advancement of nanotechnology leads the way to more personalized medicine and the use of targeted theranostics carriers for deep-seated cancers such as PDAC. New nanotechnology innovations such as specialized photo-sensitizing drug nanocarriers, can effectively improve photodynamic therapy (PDT) of PDAC and enhance phototherapy’s action through surface plasmon resonance phenomenon, as another recently re-emerged non- or minimally invasive possible treatment of such diseases. Despite the scientific advancements, significant hurdles remain and many parameters need to be examined. However, the novel application of nano-biophotonic techniques and the convergence of different science fields offer promise for the treatment of difficult-to-treat diseases, like PDAC.

Keywords

Nanomedicine / pancreatic cancer / personalized medicine / photothermal effect / photodynamic therapy / plasmonic photothermal therapy

Cite this article

Download citation ▾
Kyriakos Kokkinogoulis, Aristomenis Kollas, David Simeonidis, Pavlos Papakostas, Kalliopi Platoni, Efstathios P. Efstathopoulos, Mersini Makropoulou. An overview of the feasibility of nanomedicine in pancreatic cancer theranostics. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002326 DOI:10.37349/etat.2025.1002326

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

PANCREATIC CANCER STATISTICS [Internet]. London: World Cancer Research Fund; c2025 [cited 2024 Dec 15]. Available from: https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/#:~:text=Latest%20pancreatic%20cancer%20data,of%20pancreatic%20cancer%20in%202020

[2]

gco.iarc.fr [Internet]. Lyon: IARC; c1965-2025 [cited 2024 Dec 15]. Available from: https://gco.iarc.fr/en

[3]

Stoffel EM, Brand RE, Goggins M. Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. Gastroenterology. 2023; 164: 752-65.

[4]

Olajubutu O, Ogundipe OD, Adebayo A, Adesina SK. Drug Delivery Strategies for the Treatment of Pancreatic Cancer. Pharmaceutics. 2023; 15: 1318.

[5]

Anderson EM, Thomassian S, Gong J, Hendifar A, Osipov A. Advances in Pancreatic Ductal Adenocarcinoma Treatment. Cancers (Basel). 2021; 13: 5510.

[6]

Willink CY, Jenniskens SFM, Klaassen NJM, Stommel MWJ, Nijsen JFW. Intratumoral injection therapies for locally advanced pancreatic cancer: systematic review. BJS Open. 2023; 7: zrad052.

[7]

Caputo D. Hot topics in pancreatic cancer management. World J Gastrointest Surg. 2023; 15: 121-6.

[8]

Bown SG. Photodynamic therapy for cancer of the pancreas - The story so far. Photonics Lasers Med. 2016; 5: 91-100.

[9]

Lu L, Hu Z, Frankel W, Shen R, Chen W, Pan X, et al. Using Endoscopic Optical Coherence Tomography to Detect and Treat Early-Stage Pancreatic Cancers. Front Oncol. 2021; 11: 591484.

[10]

Ren S, Qian LC, Cao YY, Daniels MJ, Song LN, Tian Y, et al. Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma. World J Gastrointest Oncol. 2024; 16: 1256-67.

[11]

Pancreatic Cancer Treatment [Internet]. The University of Texas MD Anderson Cancer Center; c2025 [cited 2024 Dec 16]. Available from: https://www.mdanderson.org/cancer-types/pancreatic-cancer/pancreatic-cancer-treatment.html

[12]

Koukourakis IM, Desse D, Papadimitriou M, Konstadoulakis M, Zygogianni A, Papadimitriou C. Neoadjuvant treatment of pancreatic ductal adenocarcinoma: present and future. J Cancer Metastasis Treat. 2022; 8: 38.

[13]

Asadi S, Bianchi L, De Landro M, Saccomandi P. Gold Nanoparticles-Mediated Photothermal Therapy of Pancreas Using GATE: A New Simulation Platform. Cancers (Basel). 2022; 14: 5686.

[14]

Giannone F, Capretti G, Abu Hilal M, Boggi U, Campra D, Cappelli C, et al. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectability Status Criteria. Ann Surg Open. 2021; 2: e087.

[15]

Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020; 395: 2008-20.

[16]

Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018; 18: 2-11.

[17]

Gilbert JW, Wolpin B, Clancy T, Wang J, Mamon H, Shinagare AB, et al. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol. 2017; 28: 2067-76.

[18]

Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. J Invest Surg. 2023; 36: 2129884.

[19]

Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol. 2021; 11: 688377.

[20]

Schepis T, De Lucia SS, Pellegrino A, Del Gaudio A, Maresca R, Coppola G, et al. State-of-the-Art and Upcoming Innovations in Pancreatic Cancer Care: A Step Forward to Precision Medicine. Cancers (Basel). 2023; 15: 3423.

[21]

Minsky BD, Hilaris B, Fuks Z. The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manage. 1988; 3: 199-205.

[22]

Lu T, Prakash J. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer. Int J Nanomedicine. 2021; 16: 6313-28.

[23]

Tarannum M, Vivero-Escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv Drug Deliv Rev. 2022; 187: 114357.

[24]

Viegas C, Patrício AB, Prata J, Fonseca L, Macedo AS, Duarte SOD, et al. Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems. Pharmaceutics. 2023; 15: 2363.

[25]

Makropoulou M. Cancer and electromagnetic radiation therapy: Quo Vadis? arXiv:1602.02077 [Preprint]. 2016 [cited 2025 Jan 2]: [22 p.]. Available from: https://doi.org/10.48550/arXiv.1602.02077

[26]

Zheng R, Liu X, Zhang Y, Liu Y, Wang Y, Guo S, et al. Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application. Front Immunol. 2024; 15: 1383978.

[27]

nccn.org [Internet]. National Comprehensive Cancer Network; c2025 [cited 2023 Dec 13]. Available from: https://www.nccn.org/patientresources/patient-resources

[28]

Yang B, Shi J. Developing New Cancer Nanomedicines by Repurposing Old Drugs. Angew Chem Int Ed Engl. 2020; 59: 21829-38.

[29]

Greene MK, Johnston MC, Scott CJ. Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. Cancers (Basel). 2021; 13: 6175.

[30]

Kota J, Hancock J, Kwon J, Korc M. Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Lett. 2017; 391: 38-49.

[31]

Karimnia V, Slack FJ, Celli JP. Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2021; 13: 4354.

[32]

Stylianopoulos T, Munn LL, Jain RK. Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends Cancer. 2018; 4: 292-319.

[33]

Whatcott CJ, Posner RG, Von Hoff DD, Han H. Chapter 8 Desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ, Munshi HG, editors. Pancreatic Cancer and Tumor Microenvironment. Trivandrum (India): Transworld Research Network; 2012.

[34]

Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021; 14: 14.

[35]

Ren B, Cui M, Yang G, Wang H, Feng M, You L, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018; 17: 108.

[36]

Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol. 2021; 27: 5851-89.

[37]

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. ; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-25.

[38]

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-703.

[39]

Mukherji R, Debnath D, Hartley ML, Noel MS. The Role of Immunotherapy in Pancreatic Cancer. Curr Oncol. 2022; 29: 6864-92.

[40]

Xiros N, Papacostas P, Economopoulos T, Samelis G, Efstathiou E, Kastritis E, et al. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005; 16: 773-9.

[41]

Cavanna L, Stroppa EM, Citterio C, Mordenti P, Di Nunzio C, Peveri S, et al. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. Onco Targets Ther. 2019; 12: 3077-85.

[42]

Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, et al. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer. 2014; 120: 1960-7.

[43]

Ye X, Yu Y, Zheng X, Ma H. Clinical immunotherapy in pancreatic cancer. Cancer Immunol Immunother. 2024; 73: 64.

[44]

Bhamidipati D, Yedururi S, Huse J, Chinapuvvula SV, Wu J, Subbiah V. Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer. JCO Precis Oncol. 2023; 7: e2300252.

[45]

FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma [Internet]. U.S. Food and Drug Administration; [cited 2025 Jan 17]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic

[46]

Moosavi F, Hassani B, Nazari S, Saso L, Firuzi O. Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence. Biochim Biophys Acta Rev Cancer. 2024; 1879: 189185.

[47]

Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ, et al. Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. Curr Oncol Rep. 2021; 23: 68.

[48]

Wang J, Yang J, Narang A, He J, Wolfgang C, Li K, et al. Consensus, debate, and prospective on pancreatic cancer treatments. J Hematol Oncol. 2024; 17: 92.

[49]

Kareliotis G, Tremi I, Kaitatzi M, Drakaki E, Serafetinides AA, Makropoulou M, et al. Combined radiation strategies for novel and enhanced cancer treatment. Int J Radiat Biol. 2020; 96: 1087-103.

[50]

Jaidev LR, Chede LS, Kandikattu HK. Theranostic Nanoparticles for Pancreatic Cancer Treatment. Endocr Metab Immune Disord Drug Targets. 2021; 21: 203-14.

[51]

Esposito C, Crema A, Ponzetto A, Murtas G, Carloni G. Multifunctional anti-cancer nano-platforms are moving to clinical trials. Curr Drug Metab. 2013; 14: 583-604.

[52]

Feynman RP. There’s Plenty of Room at the Bottom. Caltech Eng Sci. 1960; 23: 22-36.

[53]

Nirmala MJ, Kizhuveetil U, Johnson A, G B, Nagarajan R, Muthuvijayan V. Cancer nanomedicine: a review of nano-therapeutics and challenges ahead. RSC Adv. 2023; 13: 8606-29.

[54]

Lane LA. Physics in nanomedicine: Phenomena governing the in vivo performance of nanoparticles. Appl Phys Rev. 2020; 7: 011316.

[55]

Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. 2018; 9: 1050-74.

[56]

Freitas RA. Nanomedicine, Volume I: Basic Capabilities. 1st ed. Boca Raton: CRC Press; 1999.

[57]

Mundekkad D, Cho WC. Nanoparticles in Clinical Translation for Cancer Therapy. Int J Mol Sci. 2022; 23: 1685.

[58]

Sato Y, Nakamura T, Yamada Y, Harashima H. The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS. J Control Release. 2021; 330: 305-16.

[59]

Jiang J, Cui X, Huang Y, Yan D, Wang B, Yang Z, et al. Advances and Prospects in Integrated Nano-oncology. Nano Biomed Eng. 2024; 16: 152-87.

[60]

Abdellatif AAH, Alsowinea AF. Approved and marketed nanoparticles for disease targeting and applications in COVID-19. Nanotechnol Rev. 2021; 10: 1941-77.

[61]

Kashyap BK, Singh VV, Solanki MK, Kumar A, Ruokolainen J, Kesari KK. Smart Nanomaterials in Cancer Theranostics: Challenges and Opportunities. ACS Omega. 2023; 8: 14290-320.

[62]

Bakht MK, Sadeghi M, Pourbaghi-Masouleh M, Tenreiro C. Scope of nanotechnology-based radiation therapy and thermotherapy methods in cancer treatment. Curr Cancer Drug Targets. 2012; 12: 998-1015.

[63]

Tripathi D, Hajra K, Maity D. Recent Advancement of Bio-Inspired Nanoparticles in Cancer Theragnostic. J Nanotheranostics. 2023; 4: 299-322.

[64]

Frank D, Tyagi C, Tomar L, Choonara YE, du Toit LC, Kumar P, et al. Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors. Int J Nanomedicine. 2014; 9: 589-613.

[65]

Prasad M, Lambe UP, Brar B, Shah I, J M, Ranjan K, et al. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomed Pharmacother. 2018; 97: 1521-37.

[66]

Li J, Liu F, Gupta S, Li C. Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma. Theranostics. 2016; 6: 1393-402.

[67]

Siamof CM, Goel S, Cai W. Moving Beyond the Pillars of Cancer Treatment: Perspectives From Nanotechnology. Front Chem. 2020; 8: 598100.

[68]

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy [Internet]. European Union; c 1994-2025 [cited 2025 Feb 5]. Available from: https://doi.org/10.3030/685795

[69]

New nanomedicine therapy joins the fight against pancreatic cancer [Internet]. European Union; c1994-2025 [cited 2025 Jun 3]. Available from: https://cordis.europa.eu/article/id/435743-new-nanomedicine-therapy-joins-the-fight-against-pancreatic-cancer

[70]

Bazeed AY, Day CM, Garg S. Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies. Cancers (Basel). 2022; 14: 4257.

[71]

Aquib M, Juthi AZ, Farooq MA, Ali MG, Janabi AHW, Bavi S, et al. Advances in local and systemic drug delivery systems for post-surgical cancer treatment. J Mater Chem B. 2020; 8: 8507-18.

[72]

Lambin T, Lafon C, Drainville RA, Pioche M, Prat F. Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma. World J Gastroenterol. 2022; 28: 1288-303.

[73]

De Grandis MC, Ascenti V, Lanza C, Di Paolo G, Galassi B, Ierardi AM, et al. Locoregional Therapies and Remodeling of Tumor Microenvironment in Pancreatic Cancer. Int J Mol Sci. 2023; 24: 12681.

[74]

Wang Q, Wang Z, Li Z, Li D, He F, Wang K, et al. Biomimetic camouflaged nanoparticle-based folfirinox platform for optimizing clinical pancreatic cancer treatment. Nano Today. 2023; 48: 101733.

[75]

Ren S, Song L, Tian Y, Zhu L, Guo K, Zhang H, et al. Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer. Int J Nanomedicine. 2021; 16: 7463-78.

[76]

Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001; 37: 870-7.

[77]

Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023; 8: 418.

[78]

Nedelcu A, Mocan T, Grapa C, Mocan L. Recent Advances in Nanoparticle-Mediated Diagnosis and the Treatment of Pancreatic Cancer. Int J Mol Sci. 2021; 22: 8060.

[79]

Cao B, Zhang L, Wu C, Liu X, Wang Q, Tong F, et al. Survival Outcomes and Failure Patterns in Patients with Inoperable Non-Metastatic Pancreatic Cancer Treated with Definitive Radiotherapy. Cancers (Basel). 2023; 15: 2213.

[80]

Tremi I, Spyratou E, Souli M, Efstathopoulos EP, Makropoulou M, Georgakilas AG, et al. Requirements for Designing an Effective Metallic Nanoparticle (NP)-Boosted Radiation Therapy (RT). Cancers (Basel). 2021; 13: 3185.

[81]

Saccomandi P, Lapergola A, Longo F, Schena E, Quero G. Thermal ablation of pancreatic cancer: A systematic literature review of clinical practice and pre-clinical studies. Int J Hyperthermia. 2018; 35: 398-418.

[82]

Namakshenas P, Di Matteo FM, Bianchi L, Faiella E, Stigliano S, Quero G, et al. Optimization of laser dosimetry based on patient-specific anatomical models for the ablation of pancreatic ductal adenocarcinoma tumor. Sci Rep. 2023; 13: 11053.

[83]

Kareliotis G, Chronopoulou E, Makropoulou M. In Silico, Combined Plasmonic Photothermal and Photodynamic Therapy in Mice. J Nanotheranostics. 2022; 3: 39-54.

[84]

Spyratou E, Kokkinogoulis K, Tsigaridas G, Kareliotis G, Platoni K, Makropoulou M, et al. Novel Biophotonic Techniques for Phototherapy Enhancement: Cerenkov Radiation as a Bridge between Ionizing and Non-Ionizing Radiation Treatment. J Nanotheranostics. 2023; 4: 86-105.

[85]

Spyratou E, Makropoulou M, Mourelatou EA, Demetzos C. Biophotonic techniques for manipulation and characterization of drug delivery nanosystems in cancer therapy. Cancer Lett. 2012; 327: 111-22.

[86]

Correia JH, Rodrigues JA, Pimenta S, Dong T, Yang Z. Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions. Pharmaceutics. 2021; 13: 1332.

[87]

van Straten D, Mashayekhi V, de Bruijn HS, Oliveira S, Robinson DJ. Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers (Basel). 2017; 9: 19.

[88]

Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, et al. Photodynamic therapy for cancer of the pancreas. Gut. 2002; 50: 549-57.

[89]

Karamanolis G, Mallas EG. Photodynamic therapy and pancreatic cancer. Ann Gastroenterol. 2004; 17: 15-6.

[90]

Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014; 110: 1698-704.

[91]

Shafirstein G, Bellnier D, Oakley E, Hamilton S, Potasek M, Beeson K, et al. Interstitial Photodynamic Therapy-A Focused Review. Cancers (Basel). 2017; 9: 12.

[92]

Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol. 2008; 53: R61.

[93]

Huang YY, Sharma SK, Dai T, Chung H, Yaroslavsky A, Garcia-Diaz M, et al. Can nanotechnology potentiate photodynamic therapy? Nanotechnol Rev. 2012; 1: 111-46.

[94]

Hafiz SS, Xavierselvan M, Gokalp S, Labadini D, Barros S, Duong J, et al. Eutectic Gallium-Indium Nanoparticles for Photodynamic Therapy of Pancreatic Cancer. ACS Appl Nano Mater. 2022; 5: 6125-39.

[95]

Li W, Ma Q, Wu E. Perspectives on the Role of Photodynamic Therapy in the Treatment of Pancreatic Cancer. Int J Photoenergy. 2012; 2012: 637429.

[96]

Yang H, Liu R, Xu Y, Qian L, Dai Z. Photosensitizer Nanoparticles Boost Photodynamic Therapy for Pancreatic Cancer Treatment. Nanomicro Lett. 2021; 13: 35.

[97]

Wolfsen HC. Photodynamic therapy for pancreatic cancer: let’s get serious. Gastrointest Endosc. 2008; 67: 961-3.

[98]

Pogue BW, Elliott JT, Kanick SC, Davis SC, Samkoe KS, Maytin EV, et al. Revisiting photodynamic therapy dosimetry: reductionist & surrogate approaches to facilitate clinical success. Phys Med Biol. 2016; 61: R57.

[99]

Schena E, Saccomandi P, Fong Y. Laser Ablation for Cancer: Past, Present and Future. J Funct Biomater. 2017; 8: 19.

[100]

Asadi S, Bianchi L, De Landro M, Korganbayev S, Schena E, Saccomandi P. Laser-induced optothermal response of gold nanoparticles: From a physical viewpoint to cancer treatment application. J Biophotonics. 2021; 14: e202000161.

[101]

Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine (Lond). 2007; 2: 681-93.

[102]

Bansal SA, Kumar V, Karimi J, Singh AP, Kumar S. Role of gold nanoparticles in advanced biomedical applications. Nanoscale Adv. 2020; 2: 3764-87.

[103]

Kokkinogoulis K, Kollas A, Simeonidis D, Papakostas P, Platoni K, Efstathopoulos EP, et al. PP.9.1 COMPUTATIONAL STUDY OF GOLD NANOPARTICLE'S ENHANCED PHOTOTHERMAL TREATMENT OF PANCREATIC CANCER. Physica Medica: Eur J Med Phys. 2024; 127: 104618.

[104]

Guo K, Ren S, Zhang H, Cao Y, Zhao Y, Wang Y, et al. Biomimetic Gold Nanorods Modified with Erythrocyte Membranes for Imaging-Guided Photothermal/Gene Synergistic Therapy. ACS Appl Mater Interfaces. 2023; 15: 25285-99.

[105]

Meng Y, Chen C, Lin R, Zheng L, Fan Y, Zhang M, et al. Mitochondria-Targeting Virus-Like Gold Nanoparticles Enhance Chemophototherapeutic Efficacy Against Pancreatic Cancer in a Xenograft Mouse Model. Int J Nanomedicine. 2024; 19: 14059-74.

[106]

Li J, Zheng K, Lin L, Zhang M, Zhang Z, Chen J, et al. Reprogramming the Tumor Immune Microenvironment Through Activatable Photothermal Therapy and GSH depletion Using Liposomal Gold Nanocages to Potentiate Anti-Metastatic Immunotherapy. Small. 2024; 20: 2407388.

[107]

Chen B, Zheng K, Fang S, Huang K, Chu C, Zhuang J, et al. B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC. J Nanobiotechnology. 2023; 21: 378.

[108]

Parr D. Will nanotechnology make the world a better place? Trends Biotechnol. 2005; 23: 395-8.

[109]

Shah N, Squire J, Guirguis M, Saha D, Hoyt K, Wang KK, et al. Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives. Cancers (Basel). 2022; 14: 2004.

[110]

Zhao T, Shen X, Li L, Guan Z, Gao N, Yuan P, et al. Gold nanorods as dual photo-sensitizing and imaging agents for two-photon photodynamic therapy. Nanoscale. 2012; 4: 7712-9.

[111]

Shi Z, Zhang K, Zada S, Zhang C, Meng X, Yang Z, et al. Upconversion Nanoparticle-Induced Multimode Photodynamic Therapy Based on a Metal-Organic Framework/Titanium Dioxide Nanocomposite. ACS Appl Mater Interfaces. 2020; 12: 12600-8.

[112]

Spyratou E, Kareliotis G, Makropoulou M, Efstathopoulos E, Serafetinides AA. Theoretical study of laser-based phototherapies’ improvement via upconverting nanoparticles. J Phys: Conf Ser. 2021; 1859: 012043.

[113]

Sun W, Zhou Z, Pratx G, Chen X, Chen H. Nanoscintillator-Mediated X-Ray Induced Photodynamic Therapy for Deep-Seated Tumors: From Concept to Biomedical Applications. Theranostics. 2020; 10: 1296-318.

[114]

Cline B, Delahunty I, Xie J. Nanoparticles to mediate X-ray-induced photodynamic therapy and Cherenkov radiation photodynamic therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 11: e1541.

[115]

Ran C, Zhang Z, Hooker J, Moore A. In vivo photoactivation without “light”: use of Cherenkov radiation to overcome the penetration limit of light. Mol Imaging Biol. 2012; 14: 156-62.

[116]

Hartl BA, Boucher DL, Marcu L, Cherry SR. Photodynamic Therapy Activated with Cerenkov Luminescence from Beta-Emitting Radionuclides. In: Optics in the Life Sciences. Optica Publishing Group; 2013. pp. JT2A.11.

[117]

Makropoulou M, Kareliotis G, Spyratou E, Drakaki E, Serafetinides AA, Efstathopoulos E. Non-ionizing, laser radiation in Theranostics: The need for dosimetry and the role of Medical Physics. Phys Med. 2019; 63: 7-18.

[118]

Haque M, Shakil MS, Mahmud KM. The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment. Cancers (Basel). 2023; 15: 1892.

[119]

Spyratou E, Makropoulou M, Efstathopoulos EP, Georgakilas AG, Sihver L. Recent Advances in Cancer Therapy Based on Dual Mode Gold Nanoparticles. Cancers (Basel). 2017; 9: 173.

[120]

Xu R, Lin P, Zheng J, Lin Y, Mai Z, Lu Y, et al. Orchestrating cancer therapy: Recent advances in nanoplatforms harmonize immunotherapy with multifaceted treatments. Mater Today Bio. 2025; 30: 101386.

[121]

Kareliotis G, Kalkou M, Tsigaridas G, Makropoulou M, Serafetinides AA. Assessing temperature increase during photodynamic therapy: a simulation model. J Phys: Conf Ser. 2021; 1859: 012048.

[122]

Kareliotis G, Papachristou M, Priftakis D, Datseris I, Makropoulou M. Computational study of necrotic areas in rat liver tissue treated with photodynamic therapy. J Photochem Photobiol B. 2019; 192: 40-8.

PDF (3099KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉